CLINICAL TRIALS PROFILE FOR IGALMI
✉ Email this page to a colleague
All Clinical Trials for igalmi
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT06041646 ↗ | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder | Completed | Lotus Clinical Research, LLC | Phase 4 | 2023-10-12 | This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder. |
NCT06041646 ↗ | Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder | Completed | BioXcel Therapeutics Inc | Phase 4 | 2023-10-12 | This is an in-clinic, single arm, open-label study assessing tachyphylaxis, tolerance, and withdrawal following repeated doses of Igalmi in adult males and females with agitation associated with schizophrenia or bipolar disorder. |
NCT06093451 ↗ | Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder | Recruiting | BioXcel Therapeutics Inc | Phase 4 | 2023-07-01 | An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES). Lorazepam will serve as the active control. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for igalmi
Condition Name
Clinical Trial Locations for igalmi
Trials by Country
Clinical Trial Progress for igalmi
Clinical Trial Phase
Clinical Trial Sponsors for igalmi
Sponsor Name